The hepatitis A virus (HAV) is an important cause
|
|
- Chloe Singleton
- 5 years ago
- Views:
Transcription
1 Susceptibility to Hepatitis A in Patients With Chronic Liver Disease Due to Hepatitis C Virus Infection: Missed Opportunities for Vaccination Michael Shim, Inessa Khaykis, James Park, and Edmund J. Bini Hepatitis A virus (HAV) superinfection is associated with a high risk of liver failure and death in patients with underlying chronic liver disease. Although HAV vaccination is recommended for all patients with chronic hepatitis C virus (HCV) infection, little is known about adherence to these recommendations in clinical practice. The aims of this study were to determine the frequency of HAV testing and vaccination among patients with chronic HCV infection. We conducted a retrospective cohort study of 1,193 patients diagnosed with chronic HCV infection over a 1-year period. During 1,646 person-years of follow-up, patients were seen by their primary care provider a median of 10.0 times (interquartile range, ). HAV antibody testing was performed in 640 subjects (53.6%), and 317 (49.5%) of those tested were susceptible (HAV antibody negative). Only 94 of the 1,193 patients (7.9%) received the HAV vaccine, including 26.8% of the 317 susceptible patients, 0.9% of the 323 patients who were already immune to HAV, and 1.1% of the 553 subjects who were never tested. Among the 94 vaccinated patients, 45 received only one dose of the vaccine. Three of the unvaccinated patients developed acute HAV infection during follow-up, and 1 of them died of acute liver failure. In conclusion, despite published recommendations to vaccinate against HAV in patients with chronic HCV infection, we found that HAV testing and vaccination rates were low in clinical practice. Public health programs to increase awareness about HAV vaccination in patients with chronic liver disease are needed. (HEPATOLOGY 2005;42: ) The hepatitis A virus (HAV) is an important cause of acute hepatitis worldwide, and this virus has been responsible for numerous disease outbreaks from close personal or sexual contact, 1-3 contaminated food or water, 1,4-7 injection drug use, 8,9 and other modes of transmission. 8,10 Despite the availability of the HAV vaccine since 1995, HAV infection continues to be one of the most common vaccine-preventable illnesses in the United States. 11 After adjusting for asymptomatic illness and disease underreporting, the Centers for Disease Control and Prevention estimated that 180,000 cases of HAV Abbreviations: HAV, hepatitis A virus; HCV, hepatitis C virus; VA, Veterans Affairs. From the Department of Medicine and Division of Gastroenterology, VA New York Harbor Healthcare System and NYU School of Medicine, New York, NY. Received March 9, 2005; accepted June 20, 2005 Address reprint requests to Edmund J. Bini, M.D., M.P.H., Division of Gastroenterology, VA New York Harbor Healthcare System, 423 East 23rd Street, New York, NY Edmund.Bini@med.va.gov; fax: Copyright 2005 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. infection occurred in the United States in In addition, the economic burden of acute HAV infection in the United States has been estimated at more than $300 million annually. 12 Although the overall case-fatality rate of acute HAV among persons of all ages is only 0.01% to 0.3%, 11,13,14 it is higher (1.8%) among adults 50 years of age and older. 11 More importantly, acute HAV superinfection causes severe liver disease, acute liver failure, and even higher mortality rates in patients with underlying chronic liver disease. In a prospective cohort study of adults with chronic hepatitis C virus (HCV) infection, Vento et al. 15 reported that 41.2% of patients with acute HAV superinfection developed acute liver failure, and 35.3% died. Numerous other studies have also identified chronic liver disease as a risk factor for fulminant hepatitis and death from acute HAV infection. 4,16-22 Based on the potential risk for fulminant hepatic failure and death from acute HAV superinfection, the 1996 Advisory Committee on Immunization Practices recommended HAV vaccination for all patients with chronic liver disease, including those with chronic HCV infec- 688
2 HEPATOLOGY, Vol. 42, No. 3, 2005 SHIM ET AL. 689 tion. 23 These recommendations have also been endorsed by the World Health Organization, 24 the National Institutes of Health, 25 the United States Veterans Health Administration, 26 the American Association for the Study of Liver Diseases, 27 the American Liver Foundation, 28 the American College of Gastroenterology, 29 and others However, little is known about adherence to these recommendations in clinical practice. The aims of the current study were to determine the frequency of HAV antibody testing in patients with chronic HCV infection, to evaluate the proportion of those tested who were susceptible to HAV, and to investigate whether susceptible patients were vaccinated against HAV infection according to published guidelines. Patients and Methods Study Population. We identified all patients who had HCV antibody testing performed over a 1-year period from January through December 2000 at the Veterans Affairs (VA) New York Harbor Healthcare System in New York. The VA New York Harbor Healthcare System consists of 2 main VA medical centers located in New York, NY and Brooklyn, NY. Patients were identified using our computerized patient record system and were included in this study if they were newly diagnosed as being HCV antibody and HCV RNA positive. Patients were excluded from this study if they had undetectable HCV RNA by polymerase chain reaction testing, if HCV RNA testing was not performed, or if they were co-infected with HIV. The study protocol was reviewed and approved by the Institutional Review Board at our medical center. Study Design. Demographic and clinical information were collected by reviewing the electronic medical record of all HCV-positive patients. Data collected on each patient included age, sex, race/ethnicity, current or prior injection drug use, current use of alcohol ( 3 drinks per day), active psychiatric disease, whether they were homeless, whether they had sex with a same-sex partner, history of sexually transmitted diseases, and the presence of cirrhosis. Patients were considered to have active psychiatric disease if so diagnosed by a psychiatrist and if they were receiving treatment for the condition. The diagnosis of cirrhosis was made by liver biopsy or by compatible findings on physical examination or abdominal imaging. Although our computerized record system and pharmacy database are very comprehensive, certain data (such as history of sexually transmitted diseases) were not as well documented. However, the other demographic and clinical data were complete for all patients. Follow-up data were collected through June 30, 2002 by reviewing the electronic medical record for each patient to determine the number of HCV-infected patients who had HAV antibody testing performed and the number who actually received HAV vaccination. To ensure that all patients who received the HAV vaccine were identified, we also reviewed our computerized pharmacy database. The duration of follow-up was calculated from the time of diagnosis of HCV infection until the date that the patient was last seen in the hospital or outpatient clinic. Study Outcomes. The primary outcome measure of this study was the proportion of patients with chronic HCV infection who were vaccinated against HAV. Patients were considered vaccinated if they had received at least 1 dose of any of the commercially available HAV vaccines. The secondary outcome measures included the number of doses of HAV vaccine received, whether HAV antibody testing was performed, the proportion of patients who were susceptible to HAV among those who were tested, factors associated with HAV antibody testing and HAV vaccination, and the incidence of acute HAV infection during follow-up. Susceptibility was defined as a negative total HAV antibody. Statistical Analysis. Continuous variables were compared using an unpaired t test or the Mann-Whitney U test as appropriate. Data are expressed as means SD for those variables that were normally distributed, and medians and interquartile range (25 th -75th percentile) for those with a non-normal distribution. Categorical variables are expressed as proportions and were compared using the chi-square test or Fisher s exact test. All outcomes analyses used time-to-event methods with Cox proportional-hazards models. 34 Univariate Cox regression analysis was used to identify factors associated with HAV antibody testing and HAV vaccination. Subsequently, separate multivariable Cox regression models for HAV antibody testing and HAV vaccination were created involving all variables evaluated in the univariate analyses. The multivariable analyses could then assess the independent effect of each variable in the model adjusted for the effects of each of the other variables. The strength of the association between covariates and HAV testing as well as HAV vaccination are expressed as hazard ratios (HR)with 95% confidence intervals (CI). Statistical analysis was performed using SPSS software version 13.0 for Windows (SPSS Inc., Chicago, IL), and a two-tailed P value of less than.05 was considered statistically significant. Results Demographic and Clinical Characteristics. During the 1-year study period, a total of 8,203 patients had
3 690 SHIM ET AL. HEPATOLOGY, September 2005 Fig. 1. Flow of patients through the study. Table 1. Demographic and Clinical Characteristics of the 1,193 Patients With Chronic HCV Infection Age, yr* 53.0 ( ) Male 1,164 (97.6%) Race/ethnicity Non-Hispanic white 381 (31.9%) Non-Hispanic black 576 (48.3%) Hispanic or Latino 221 (18.5%) Other 15 (1.3%) Injection drug use 699 (58.6%) Alcohol use 388 (32.5%) Homeless 192 (16.1%) Active psychiatric disease 449 (37.6%) Sex with same-sex partner 44 (3.7%) Prior sexually transmitted disease 104 (8.7%) Cirrhosis 110 (9.2%) *Data are expressed as median (25th-75th percentile). HCV antibody testing performed, of whom 1,363 (16.6%) were HCV antibody and HCV RNA positive. The flow of patients through the study is shown in Fig. 1. Of the 1,363 patients, 1,193 had chronic HCV infection and met our study eligibility criteria. The baseline demographic and clinical characteristics of these 1,193 patients are shown in Table 1. Most patients were male, and the population was ethnically diverse. Histories of injection drug use, alcohol abuse, and psychiatric disease were highly prevalent in our subjects. HAV Antibody Testing. During a total of 1,646 person-years of follow-up, the median number of times that patients were seen by their primary care provider for any reason was 10.0 (IQR, ). A total of 469 (39.3%) of the 1,193 patients were seen in the Gastroenterology clinic at least once during follow-up. Despite the high frequency of follow-up visits, HAV antibody testing was only performed in 640 (53.6%; 95% CI, 50.8%-56.5%) of the 1,193 patients with chronic HCV infection. To better characterize HAV testing among patients with chronic HCV infection, we determined the proportion of patients who had HAV antibody testing performed according to select demographic and clinical characteristics (Table 2). In the unadjusted Cox proportional hazards analysis, older patients were less likely to have HAV antibody testing performed, whereas patients with a prior sexually transmitted disease and individuals seen in our gastroenterology clinic were more likely to be tested. After adjusting for potential confounding variables, multivariable Cox regression analysis found that older patients and those with active psychiatric disease were less likely to have HAV antibody testing performed, whereas patients with a prior sexually transmitted disease and individuals seen in our gastroenterology clinic were more likely to be tested (Table 2). Susceptibility to HAV Infection. Among the 640 patients who had HAV antibody testing performed, 323 (50.5%; 95% CI, 46.5%-54.4%) were immune to HAV, and 317 (49.5%; 95% CI, 45.6%-53.5%) were susceptible. Susceptibility to HAV declined with age, was higher in women than in men, and differed according to race/ ethnicity (Table 3). In addition, susceptibility to HAV was significantly greater in those who used injection drugs, whereas it was lower in persons who had sex with a same-sex partner and those with a prior sexually transmitted disease. HAV Vaccination. During follow-up, only 94 of the 1,193 patients (7.9%; 95% CI, 6.4%-9.6%) with chronic HCV infection received 1 or more doses of the HAV vaccine; none of the patients was vaccinated against HAV before the diagnosis of HCV infection. The vaccine was administered to 85 of the 317 patients (26.8%) who were susceptible to HAV, 3 of the 323 patients (0.9%) who were already immune to HAV, and 6 of the 553 subjects (1.1%) who never had HAV testing. Among the 94 vaccinated patients, 45 received only 1 dose of the vaccine, 41 received 2 doses, and 8 received 3 or more doses. All 8 patients who received 3 or more doses of the vaccine received more than the recommended number of doses of the commercially available HAV vaccine; none received the combined HAV and hepatitis B vaccine. Of the 94 patients who received the HAV vaccine, 88 (93.6%) had HAV antibody testing before vaccination. Patients who had HAV antibody testing performed were significantly more likely to receive the HAV vaccine as compared with those who never had
4 HEPATOLOGY, Vol. 42, No. 3, 2005 SHIM ET AL. 691 Table 2. Factors Associated With HAV Antibody Testing According to Select Demographic and Clinical Characteristics (N 1,193) Characteristic Number of Subjects Proportion Tested for HAV (%) Unadjusted Adjusted HR (95% CI) P Value* HR (95% CI) P Value* Age, yr (reference) 1.00 (reference) ( ) ( ) ( ) ( ) and older ( ) ( ).12 Sex Female (reference) 1.00 (reference) Male 1, ( ) ( ).61 Race/ethnicity Non-Hispanic white (reference) 1.00 (reference) Non-Hispanic black ( ) ( ).92 Hispanic or Latino ( ) ( ).78 Other ( ) ( ).35 Injection drug use No (reference) 1.00 (reference) Yes ( ) ( ).41 Alcohol use No (reference) 1.00 (reference) Yes ( ) ( ).11 Homeless No 1, (reference) 1.00 (reference) Yes ( ) ( ).82 Active psychiatric disease No (reference) 1.00 (reference) Yes ( ) ( ).009 Sex with same-sex partner No 1, (reference) 1.00 (reference) Yes ( ) ( ).58 Prior sexually transmitted disease No 1, (reference) 1.00 (reference) Yes ( ) ( ).001 Cirrhosis No 1, (reference) 1.00 (reference) Yes ( ) ( ).94 Seen in gastroenterology clinic No (reference) 1.00 (reference) Yes ( ) ( ).008 *The P values were derived from Cox regression analysis. HAV testing (HR, 9.12; 95% CI, ). Among the 1,099 patients who did not receive the HAV vaccine, documentation that they refused the vaccine was only noted for 2 patients. To further evaluate HAV vaccination among patients with chronic HCV infection, we determined the proportion of patients who received at least 1 dose of the HAV vaccine according to select demographic and clinical characteristics (Table 4). In the unadjusted Cox proportional hazards analysis, older patients and Hispanics were less likely to be vaccinated, whereas patients with cirrhosis and those seen in the gastroenterology clinic were more likely to receive the HAV vaccine. After adjusting for potential confounding variables, multivariable Cox regression analysis found that older patients and Hispanics were significantly less likely to be vaccinated, whereas being seen in our gastroenterology clinic was strongly associated with an increased likelihood of receiving the HAV vaccine (Table 4). Incidence of Acute HAV Infection. A total of 3 of the 1,193 patients with chronic HCV infection developed acute HAV infection during 1,646 person-years of follow-up, an incidence rate of 1.82 per 1,000 person-years. The 3 patients were men, and all had elevations of alanine aminotransferase levels greater than 25 times the upper limit of normal and were IgM HAV antibody positive at the time of diagnosis of acute HAV-associated hepatitis. The potential risk factors for acute HAV infection in these 3 men included injection drug use, unprotected anal intercourse with another man, and travel to an endemic area. Among these 3 patients, 1 died of acute liver failure, corresponding to a case-fatality rate of 33.3%. All 3 of
5 692 SHIM ET AL. HEPATOLOGY, September 2005 Table 3. Proportion of Patients Susceptible to HAV Infection According to Select Demographic and Clinical Characteristics (N 640) Characteristic these patients were known to be HAV antibody negative in the past, and none of them received the HAV vaccine. Discussion Number of Subjects Proportion Susceptible to HAV (%) P Value* Age, yr and older Sex.08 Female Male Race/ethnicity.03 Non-Hispanic white Non-Hispanic black Hispanic or Latino Other Injection drug use.001 No Yes Alcohol use.28 No Yes Homeless.28 No Yes Active psychiatric disease.66 No Yes Sex with same-sex partner.005 No Yes Prior sexually transmitted disease.001 No Yes Cirrhosis.74 No Yes NOTE: Susceptible was defined as a negative total HAV antibody. *The P values were calculated using the chi square test. In a large retrospective cohort study, we showed that a substantial proportion of patients with chronic HCV infection did not have HAV antibody testing performed, and most of the susceptible patients were never vaccinated against HAV. The low rates of HAV testing and vaccination are striking given the presence of recommendations to vaccinate these individuals against HAV since 1996, the long duration of follow-up, and the high number of visits with their primary care provider. These findings have substantial public health implications and represent missed opportunities for prevention. Among our 1,193 patients with chronic HCV infection, only 53.6% had HAV antibody testing performed. These findings were similar to a retrospective study by Siddiqui et al., 35 which showed that HAV testing was performed in 61.4% of patients with chronic HCV infection. The reasons for these low rates of HAV testing are likely multifactorial, including patient barriers, provider barriers, and other system-based factors. Patient-related barriers potentially include refusal and poor compliance, whereas provider-related barriers may include lack of knowledge regarding HAV antibody testing, lack of time or resources, or other unidentified reasons. It is also possible that providers did not order HAV antibody testing because they did not believe that it was necessary. The need for pre-vaccination antibody testing in these patients remains controversial. It may be costeffective to offer pre-vaccination testing in populations with a high prevalence of natural immunity to HAV, whereas universal vaccination (vaccination of all patients without pre-testing) may be more appropriate in populations with a low prevalence of immunity. 11,36 However, a universal vaccination strategy is an unlikely explanation for the low testing rates in our population, given that only 6 of the 553 patients who were not tested for HAV were vaccinated. Among the 640 patients who had HAV antibody testing in our study, 49.5% were HAV antibody negative and were susceptible to HAV infection. The proportion of susceptible patients in our study was similar to that of other studies but lower than the 62.4% percent reported by Siddiqui at al. 35 or the 67% susceptibility to HAV found in the general population of the United States. 11 These differences may be explained by differences in the patient populations studied. Our patients were older than the subjects included in the United States seroprevalence study and included a high proportion of men and Hispanics, subgroups that have a high prevalence of natural immunity to HAV. 11 In addition to the low rates of HAV antibody testing in our patients, we also found that an even lower proportion (94/1,193; 7.9%) was vaccinated against HAV. More importantly, only 26.8% of patients who were known to be susceptible to HAV received at least 1 dose of the HAV vaccine. To date, we are only aware of 1 other study that has addressed HAV vaccination rates among patients with chronic liver disease in clinical practice. In a random sample of 105 patients with cirrhosis who were referred for liver transplantation, 26.3% of the 76 susceptible patients had been vaccinated against HAV. 40 These findings underscore the need to implement educational programs and other interventions to improve vaccination rates in this population. The reasons for the low vaccination rates in our study are unknown. In addition to the patient-related barriers
6 HEPATOLOGY, Vol. 42, No. 3, 2005 SHIM ET AL. 693 Table 4. Factors Associated With Receiving At Least One Dose of the HAV Vaccine According to Select Demographic and Clinical Characteristics (N 1,193) Characteristic Number of Subjects Proportion Vaccinated (%) Unadjusted Adjusted HR (95% CI) P Value* HR (95% CI) P Value* Age, yr (reference) 1.00 (reference) ( ) ( ) ( ) ( ) and older ( ) ( ).006 Sex Female (reference) 1.00 (reference) Male 1, ( ) ( ).76 Race/ethnicity Non-Hispanic white (reference) 1.00 (reference) Non-Hispanic black ( ) ( ).35 Hispanic or Latino ( ) ( ).002 Other ( ) ( ).96 Injection drug use No (reference) 1.00 (reference) Yes ( ) ( ).68 Alcohol use No (reference) 1.00 (reference) Yes ( ) ( ).10 Homeless No 1, (reference) 1.00 (reference) Yes ( ) ( ).52 Active psychiatric disease No (reference) 1.00 (reference) Yes ( ) ( ).48 Sex with same-sex partner No 1, (reference) 1.00 (reference) Yes ( ) ( ).31 Prior sexually transmitted disease No 1, (reference) 1.00 (reference) Yes ( ) ( ).63 Cirrhosis No 1, (reference) 1.00 (reference) Yes ( ) ( ).20 Seen in Gastroenterology clinic No (reference) 1.00 (reference) Yes ( ) ( ).001 *The P values were derived from Cox regression analysis. for HAV testing discussed above, patients may not have received the HAV vaccine because of a lack of awareness that the vaccine was necessary, belief that they were not at risk for HAV infection, doubts about vaccine efficacy, misperceptions about vaccine side effects, fear of needles, or other reasons. Alternatively, it is possible that HAV vaccination was not offered by providers because of the need to address other more important issues during clinic visits, inadequate reimbursement, lack of knowledge about whom to vaccinate, or the belief that vaccination is not safe, effective, or cost-effective in this population. However, several studies have shown that vaccination against HAV is safe and effective in patients with chronic liver disease, especially in those with well-compensated liver disease. 41,42 In addition, HAV vaccination has been shown to be cost-effective in patients with chronic liver disease. 43,44 Although the HAV vaccine is also safe in patients with decompensated disease and in liver transplant recipients, the immunogenicity of the vaccine is substantially lower than in those with compensated liver disease. 42,45,46 Therefore, early vaccination against HAV is important in patients with chronic liver disease. Another important finding in our study was that only half of the patients who were vaccinated received the full vaccination course. Although the HAV vaccine is effective in patients with chronic liver disease, the geometric mean titer of HAV antibody induced by the vaccine in these patients is lower than in those without chronic liver disease, and, therefore, high rates of protection against HAV are only achieved after the administration of both doses of the vaccine. 41,42,47 Although some of our patients who received only one dose of the vaccine completed the full
7 694 SHIM ET AL. HEPATOLOGY, September 2005 course after our study ended, it does raise some concerns that these individuals may not be adequately protected against HAV infection. Additional studies are needed to determine whether an accelerated vaccination schedule 48 or the use of the combination HAV and hepatitis B virus vaccine 49 improves physician and patient compliance with vaccination. In addition to demonstrating that HAV testing and vaccination rates were low in patients with chronic HCV infection, we determined that the incidence rate of acute HAV infection in our subjects was 1.82 per 1,000 personyears. More importantly, 1 of the 3 patients who developed acute HAV infection died of acute liver failure, and this case-fatality rate was similar to what has been reported by other investigators. 15 Unfortunately, all 3 of these patients had been tested for HAV antibodies before the development of acute HAV infection, but none of them was vaccinated despite documentation that they were susceptible. Although the number of patients with acute HAV infection in our study was small, this finding highlights the risk of morbidity and mortality from acute HAV infection in patients with underlying chronic liver disease and underscores the importance of HAV vaccination in these individuals. The strengths of the current study include the large number of HCV-infected patients, the availability of long-term follow-up data, and the use of the computerized patient record system and pharmacy database to obtain detailed demographic and clinical data. However, there are some limitations of this study that should be considered when interpreting our findings. Although the most obvious limitation of this investigation was the retrospective study design, we believe that it would be difficult to conduct this study prospectively because it would likely influence patient and provider behaviors and bias the results. Another limitation of this study is that it was performed at a single VA healthcare system, and most of our patients were men. Therefore, our findings may not be generalizable to other VA medical centers, non-va settings, or women. Finally, the reasons for the low HAV testing and vaccination rates in patients with chronic HCV infection could not be determined in our study. It is likely that the low testing and vaccination rates were due to a combination of factors, including patient barriers, provider barriers, and other unidentified variables. Alternatively, we may have underestimated HAV testing and vaccination rates because some patients received these outside of the VA health care system. However, this is not likely to have been a common event because the patients were followed up closely and had a median of 10 visits with their primary care provider. Furthermore, even if they did receive testing and vaccination at another facility, these issues should have been addressed by our primary care providers and documented in the electronic medical record. In conclusion, despite published recommendations to vaccinate against HAV in patients with chronic HCV infection, we found that HAV testing and vaccination rates were low in clinical practice. These findings are particularly important given the high risk of acute liver failure from HAV superinfection in patients with underlying chronic liver disease, as well as data demonstrating that HAV vaccination is safe, effective, and cost-effective in this population. Public health efforts aimed at raising awareness about HAV vaccination in patients with chronic liver disease should be strongly encouraged. In addition, further studies to evaluate patient and provider barriers to HAV vaccination are needed to prevent future missed opportunities for vaccination. References 1. Keeffe EB. Occupational risk for hepatitis A: a literature-based analysis. J Clin Gastroenterol 2004;38: Centers for Disease Control and Prevention. Public health dispatch: multistate outbreak of hepatitis A among young adult concert attendees United States, MMWR Morb Mortal Wkly Rep 2003;52: Cotter SM, Sansom S, Long T, Koch E, Kellerman S, Smith F, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis 2003;187: Cooksley WG. What did we learn from the Shanghai hepatitis A epidemic? J Viral Hepat 2000;7(Suppl 1): Fiore AE. Hepatitis A transmitted by food. Clin Infect Dis 2004;38: Centers for Disease Control and Prevention. Foodborne transmission of hepatitis A Massachusetts, MMWR Morb Mortal Wkly Rep 2003;52: Hutin YJ, Pool V, Cramer EH, Nainan OV, Weth J, Williams IT, et al. A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team. N Engl J Med 1999;340: Franco E, Giambi C, Ialacci R, Coppola RC, Zanetti AR. Risk groups for hepatitis A virus infection. Vaccine 2003;21: O Donovan D, Cooke RP, Joce R, Eastbury A, Waite J, Stene-Johansen K. An outbreak of hepatitis A amongst injecting drug users. Epidemiol Infect 2001;127: Koff RS. Hepatitis A. Lancet 1998;351: Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48: Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M. The cost of hepatitis A infections in American adolescents and adults in HEPATOLOGY 2000;31: Bianco E, Stroffolini T, Spada E, Szklo A, Marzolini F, Ragni P, et al. Case fatality rate of acute viral hepatitis in Italy: : an update. Dig Liver Dis 2003;35: Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, et al. The diverse patterns of hepatitis A epidemiology in the United Statesimplications for vaccination strategies. J Infect Dis 1998;178: Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:
8 HEPATOLOGY, Vol. 42, No. 3, 2005 SHIM ET AL Wang JY, Lee SD, Tsai YT, Lo KJ, Chiang BN. Fulminant hepatitis A in chronic HBV carrier. Dig Dis Sci 1986;31: Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 1989;110: Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90: Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N, Attamasirikul K. Acute, hepatitis-a super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol 1999;93: Lefilliatre P, Villeneuve JP. Fulminant hepatitis A in patients with chronic liver disease. Can J Public Health 2000;91: Kyrlagkitsis I, Cramp ME, Smith H, Portmann B, O Grady J. Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center. Hepatogastroenterology 2002;49: Almasio PL, Amoroso P. HAV infection in chronic liver disease: a rationale for vaccination. Vaccine 2003;21: Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996;45: World Health Organization. Public health control of hepatitis A: memorandum from a WHO meeting. Bull World Health Organ 1995;73: National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 June 10-12, HEPATOLOGY 2002;36(Suppl):S3-S Department of Veterans Affairs. Hepatitis C Virus (HCV) Testing and Prevention Counseling Guidelines for VA Health Care Practitioners. Available at: pdf. Accessed January 6, Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39: American Liver Foundation. Position Statement on Hepatitis A and Vaccination. Available at Accessed January 17, American College of Gastroenterology. Chronic Liver Disease: A Primer for Vaccinations. Available at: publications/index.html. Accessed December 15, Cooksley WG. Consensus statement on the role of hepatitis A vaccination in patients with chronic liver disease. J Viral Hepat 2000;7(Suppl 1): Crowcroft NS, Walsh B, Davison KL, Gungabissoon U. Guidelines for the control of hepatitis A virus infection. Commun Dis Public Health 2001; 4: Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol 2001;33: Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004;19: Cox DR. Regression models and life tables. J R Stat Soc 1972;34: Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001;96: Duncan M, Hirota WK, Tsuchida A. Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis. Am J Gastroenterol 2002;97: Sjogren MH. Preventing acute liver disease in patients with chronic liver disease. HEPATOLOGY 1998;27: Kiefer LA, Honish A, Predy G, Talbot JA. The seroprevalence of hepatitis A and B in people testing positive for hepatitis C. CMAJ 2000;162: Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepatol 2005;12: Arguedas MR, McGuire BM, Fallon MB. Implementation of vaccination in patients with cirrhosis. Dig Dis Sci 2002;47: Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. HEPATOLOGY 1998;27: Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. HEPATOLOGY 2001;34: Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97: Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002;97: Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999;94: Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001;72: Lee SD, Chan CY, Yu MI, Wang YJ, Chang FY, Lo KJ, et al. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol 1997;52: Nothdurft HD, Dietrich M, Zuckerman JN, Knobloch J, Kern P, Vollmar J, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002;20: Joines RW, Blatter M, Abraham B, Xie F, De Clercq N, Baine Y, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 2001;19:
Seroprevalence of anti-hav among patients with chronic viral liver disease
Online Submissions: http://www.wjgnet.com/7-9327office wjg@wjgnet.com doi:10.3748/wjg.v17.i2.236 World J Gastroenterol 2011 January 14; 17(2): 236-241 ISSN 7-9327 (print) ISSN 2219-2840 (online) 2011 Baishideng.
More informationSeroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province
IJPM Seroprevalence of Hepatitis A in Patients with Chronic Hepatitis C in Isfahan Province Parisa Shoaei 1, Laleh Zeidabadinejad 1, Razieh Hassannejad 1, Behrooz Ataei 1, Majid Yaran 1, Nazila Kassaian
More informationEmerging Need for Vaccination against Hepatitis A Virus in Patients with Chronic Liver Disease in Korea
J Korean Med Sci 7; 22: 218-22 ISSN 111-8934 Copyright The Korean Academy of Medical Sciences Emerging Need for Vaccination against Hepatitis A Virus in Patients with Chronic Liver Disease in Korea Vaccination
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationEpidemiology of hepatitis E infection in Hong Kong
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Epidemiology of hepatitis E infection in Hong Kong DPC Chan *, KCK Lee, SS Lee K e y M e s s a g e s 1. The overall anti hepatitis E virus (HEV) seropositivity
More informationHepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States
Journal of Substance Abuse Treatment 42 (2012) 438 445 Brief article Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States Edmund J. Bini,
More informationCost-effectiveness of Hepatitis A and Hepatitis B Vaccination for Jail Inmates
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2007 Cost-effectiveness of Hepatitis A and Hepatitis B Vaccination
More informationThe Use of a Combination Vaccine in International Travelers Visiting Countries with High Endemic Rates of Hepatitis A and/or Hepatitis B
American Journal of Infectious Diseases 4(2): 104-108, 2008 ISSN 1553-6203 2008 Science Publications The Use of a Combination Vaccine in International Travelers Visiting Countries with High Endemic Rates
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationTRANSPARENCY COMMITTEE OPINION. 19 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 May 2010 HAVRIX 1440 U/1 ml ADULTES, suspension for injection in prefilled syringe. Hepatitis A virus (inactivated,
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationVaccination of patients with chronic viral hepatitis against Hepatitis A and Hepatitis B
Vaccination of patients with chronic viral hepatitis against Hepatitis A and Hepatitis B Professor Sergey L. Mukomolov Saint-Petersburg Pasteur Institute WHITE NIGHTS OF HEPATOLOGY 2013 6-7 June Saint-Peterburg
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationEpidemiology Update Hepatitis A
December 2011 Epidemiology Update Hepatitis A Hepatitis A Key Points Between 2000 and 2010, 209 cases of hepatitis A were reported in Hennepin County residents. This represents 30% of the cases reported
More informationEpidemiology and Screening for Hepatitis C Infection
Epidemiology and Screening for Hepatitis C Infection Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Epidemiology/Screening for Hepatitis
More information26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges
Rate per, Types of Viral Hepatitis A E B D C Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Source of virus Feces Feces Blood/bloodderived body fluids
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Hepatitis A Virus United States,
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Hepatitis A Virus United States, 1987 2017 122 nd AFDO Annual Educational Conference, June 9-13, 2018, Burlington, VT Vincent J Radke,
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationHepatitis A Antibodies in Liver Transplant Recipients: Evidence for Loss of Immunity Posttransplantation
Hepatitis A Antibodies in Liver Transplant Recipients: Evidence for Loss of Immunity Posttransplantation Mehmet Arslan, Russell H. Wiesner, John J. Poterucha, John B. Gross, Jr, and Nizar N. Zein Liver
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationHepatitis C (HCV) Digestive Health Recognition Program
PQRS #84 Hepatitis C: Ribonucleic Acid (RNA) Effective Clinical Process NQF 0395 Testing Before Initiating Treatment Care Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis
More informationHepatitis C virus (HCV) is the most common
Meeting Vaccination Quality Measures for Hepatitis A and B Virus in Patients with Chronic Hepatitis C Infection Jennifer R. Kramer, 1,2 Christine Y. Hachem, 5 Fasiha Kanwal, 4,5 Minghua Mei, 1,2 and Hashem
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationDeclining Hepatitis A Mortality in the United States during the Era of Hepatitis A Vaccination
MAJOR ARTICLE Declining Hepatitis A Mortality in the United States during the Era of Hepatitis A Vaccination Tara M. Vogt, 1 Matthew E. Wise, 2 Beth P. Bell, 1,a and Lyn Finelli 1,a 1 Division of Viral
More informationHepatitis A Related Mortality in California, : Analysis of Multiple Cause Coded Death Data
Hepatitis A Related Mortality in California, 1989 2: Analysis of Multiple Cause Coded Death Data Matthew E. Wise, MPH, and Frank Sorvillo, MPH, PhD Hepatitis A virus (HAV) infection continues to cause
More informationOpen Access Ongoing Care and Follow-up Behavior of Working Age Japanese with Hepatitis C Virus
Send Orders for Reprints to reprints@benthamscience.net The Open Public Health Journal, 2014, 7, 1-5 1 Open Access Ongoing Care and Follow-up Behavior of Working Age Japanese with Hepatitis C Virus Koji
More informationHepatitis B in Africa: Epidemiology, Pathophysiology and Challenges
Gilead-sponsored symposium at the 11th INTEREST Workshop 2017 Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Ponsiano Ocama Department of Medicine Makerere University College of Health
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationThe Cost-Effectiveness of Hepatitis A Vaccination in Patients With Chronic Hepatitis C
Original Articles The Cost-Effectiveness of Hepatitis A Vaccination in Patients With Chronic Hepatitis C ROBERT P. MYERS, JAMES C. GREGOR, AND PAUL J. MAROTTA Infection with hepatitis A virus (HAV) occasionally
More informationThe Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study
The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study DK Li, YJ Ren, DS Fierer, S Rutledge, OS Shaikh, V Lo
More informationImproving Access & Linkage to Care in Underserved Populations & Baby Boomers
Improving Access & Linkage to Care in Underserved Populations & Baby Boomers Lesley Miller MD Medical Director, Grady Liver Clinic Associate Professor of Medicine Division of General Medicine and Geriatrics
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationMULTICENTRIC EVALUATION OF NEW COMMERCIAL ENZYME IMMUNOASSAYS FOR THE DETECTION OF IGM AND TOTAL ANTIBODIES AGAINST HEPATITIS A
CVI Accepts, published online ahead of print on June 0 Clin. Vaccine Immunol. doi:./cvi.000- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationHepatitis Case Investigation
* indicates required fields Does patient also have: Hepatitis Case Investigation West Virginia Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology
More informationHepatitis A Vaccination: Is It Necessary For Thai Adults?
ISPUB.COM The Internet Journal of Asthma, Allergy and Immunology Volume 3 Number 2 Hepatitis A Vaccination: Is It Necessary For Thai Adults? S Sugaroon, V Wiwanitkit Citation S Sugaroon, V Wiwanitkit.
More informationHepatitis A and B Immunity and Vaccination in Chronic Hepatitis B and C Patients in a Large United States Cohort
MAJOR ARTICLE Hepatitis A and B Immunity and Vaccination in Chronic Hepatitis B and C atients in a Large United States Cohort Emily Henkle, 1 Mei Lu, 2 Lora B. Rupp, 2 Joseph A. Boscarino, 3 Vinutha Vijayadeva,
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationEpidemiology of HCV infection among HD pts in Iran and prevention strategies
Epidemiology of HCV infection among HD pts in Iran and prevention strategies B. Einollahi Professor of Internal Medicine/Nephrology Division Baqiyatallah University of Medical Sciences 4th International
More informationHepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003
Hepatitis 2003 STARS Program Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Outline n Hepatitis A Epidemiology and screening Transmission n Hepatitis B Epidemiology
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More information2018 Adult Immunization Schedule
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases 2018 Adult Immunization Schedule National Adult Immunization Coordinators Partnership Quarterly Meeting
More informationHAV and HBV seroprevalence in 1,000 patients with chronic HCV infection in a Tertiary Care Center in São Paulo, Brazil
ORIGINAL ARTICLE September-October, Vol. 15 No. 5, 2016: 691-695 691 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian
More informationHBV in the UK: economic aspects
HBV in the UK: economic aspects J Edmunds 1, R Siddiqui 1, S Hahne 2, N Gay 1, A Sutton 1, M Ramsay 2 1 Modelling & Economics Unit, HPA Centre for Infections 2 Immunisation Dept., HPA Centre for Infections
More informationPrevention of Hepatitis A with the Hepatitis A Vaccine
The new england journal of medicine clinical practice Prevention of Hepatitis A with the Hepatitis A Vaccine Allen S. Craig, M.D., and William Schaffner, M.D. This Journal feature begins with a case vignette
More informationHEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)
Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationHepatitis B Risks and Immunization Coverage Among American Travelers
273 Hepatitis B Risks and Immunization Coverage Among American Travelers Bradley A. Connor, MD, * R. Jake Jacobs, MPA, and Allen S. Meyerhoff, MS * Division of Gastroentesiogy and Hepatology, Weill Medical
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationPREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS
PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS Holly Hagan, PhD Professor Co-Director, Center for Drug Use and HIV Research Principal Investigator, HCV Synthesis Project New York University HCV prevalence
More informationDuring the past 2 decades, an increase in the ageadjusted
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:104 110 Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study JESSICA A. DAVILA* and HASHEM B. EL SERAG*,
More informationIncreasing Trends in Transplantation of HCV-positive Livers into Uninfected Recipients
Accepted Manuscript Increasing Trends in Transplantation of HCV-positive Livers into Uninfected Recipients George Cholankeril, MD, Andrew A. Li, MD, Brittany B. Dennis, PhD, Alice E. Toll, MS, Donghee
More informationZobair M. Younossi M.D., M.P.H., FACG
HCV Epidemiology and Cohort Screening Guidelines Zobair M. Younossi, MD, MPH, FACG Consultant or Advisor: Conatus, Enterome, Gilead, Merck, Salix, Vertex, J & J HCV Epidemiology and Cohort Screening Guidelines
More informationUpdate on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
More informationTRANSPARENCY COMMITTEE OPINION. 19 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 May 2010 HAVRIX NOURRISSONS ET ENFANTS 720 U/0.5 ml, suspension for injection in prefilled syringe. Inactivated,
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Hepatitis A Virus
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Hepatitis A Virus Monique A. Foster, MD MPH LCDR, United States Public Health Service Medical Epidemiologist, Division of Viral Hepatitis
More informationManagement of Acute HCV Infection
Management of Acute HCV Infection This section provides guidance on the diagnosis and medical management of acute HCV infection, which is defined as presenting within 6 months of the exposure. During this
More informationHepatitis B Vaccination among Physicians, Dentists and Nurses in Bahrain
Bahrain Medical Bulletin, Vol. 35, No. 4, December 2013 Hepatitis B Vaccination among Physicians, Dentists and Nurses in Bahrain Sameer Abdulla Al-Haddad, MD, ABFM, MSc* Jaleela S Jawad, MD, ABFM, MSc**
More informationi Screening and Natural History
HCV Epidemiology, i Screening and Natural History BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Hepatitis
More informationRoutine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002
Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002 Ann R. Fingar, MD, MPH, and Byron J. Francis, MD, MPH Burden of suffering Vaccines are available
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More informationKaren E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago
Karen E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago 1 2 billion people have been exposed to HBV 350-400 million people chronically
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationViral Hepatitis - Historical Perspective
Viral Hepatitis - Historical Perspective Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D F, G,? other C Parenterally transmitted Before the discovery of hepatitis A virus (HAV) and
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationHBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board
HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest
More informationClinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States
Clinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States Linda Beer, PhD, Christine L. Mattson, PhD, Joseph Prejean, PhD, and Luke Shouse, MD 10 th International
More informationHepatitis. Epidemiology and Prevention of Viral Hepatitis A, B, and C:
Epidemiology and Prevention of Viral Hepatitis A, B, and C: An Overview Andrea L. Cox, M.D., Ph.D. The Viral Hepatitis Center The Johns Hopkins University Hepatitis Inflammation of the liver Can be caused
More informationStrategies to Address HCV
Strategies to Address HCV HIV Programs & U.S. Viral Hepatitis Action Plan Corinna Dan, RN, M.P.H. Viral Hepatitis Policy Advisor Office of HIV/AIDS and Infectious Disease Policy September 10, 2015 1 The
More informationEpidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur
Epidemiology of Hepatitis B in sub-saharan Africa 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur From the Big Three to the Big Four 1600000 Number of deaths/year 1400000 HAV + HEV 1200000 1000000
More informationGender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project,
Gender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project, 2009-2010 Linda Beer PhD, Christine L Mattson PhD, William Rodney Short MD,
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationHepatitis E in developing countries
Hepatitis E in developing countries Hepatitis E in developing countries Rakesh Aggarwal Department of Gastroenterology Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India Forms Epidemic
More informationPHSKC HIV Testing Survey: Knowledge, Attitudes and Practices
PHSKC HIV Testing Survey: Knowledge, Attitudes and Practices Page One This anonymous survey is intended to collect information about HIV testing attitudes and practices. Results will be used by Public
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationHEPATITIS A. Figure 35. Figure 36. Hepatitis A Incidence Rates by Year LAC and US,
HEPATITIS A CRUDE DATA Number of Cases 839 Annual Incidence a LA County 9.1 California 9. United States 4.9 Age at Onset Mean 27 Median 22 Range months - 97 years Case Fatality LA County.% United States
More informationHepatitis A and B outbreaks in Massachusetts,
Hepatitis A and B outbreaks in Massachusetts, 2017-2018 Shauna Onofrey, MPH Viral Hepatitis Surveillance Coordinator Massachusetts Department of Public Health Massachusetts Background Population: 6.86
More informationHepatitis A Virus Infections
Hepatitis A Virus Infections Robert L. Brawley, MD, MPH, FSHEA Chief, Infectious Disease Branch Division of Epidemiology and Health Planning Kentucky Department for Public Health Objectives Discuss the
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationInternist Diagnosis and Management of Chronic Hepatitis B Virus Infection
UPDATE IN OFFICE MANAGEMENT Internist Diagnosis and Management of Chronic Hepatitis B Virus Infection Brian J. McMahon, MD, a Joan Block, RN, BSN, b Barbara Haber, MD, c Thomas London, MD, d James A. McHugh,
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationTrends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans
Clinical Gastroenterology and Hepatology 2016;14:301 308 Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans Fasiha Kanwal,*,, Jennifer R. Kramer,*, Zhigang Duan,*,
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More information